Clinical impact of tumour biology in the management of gastroesophageal cancer

Nature Reviews Clinical Oncology

Volumn 13, Issue 6, 2016, Pages 348-360

  Lordick, Florian ^a   Janjigian, Yelena Y ^b  

^a University Cancer Center Leipzig (UCCL)   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 4547; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; ONARTUZUMAB; PACLITAXEL; PEMBROLIZUMAB; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE; RADIOPHARMACEUTICAL AGENT; RAMUCIRUMAB; REGORAFENIB; RILOTUMUMAB; SORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KDR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER STEMNESS; CANCER SURVIVAL; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG RESEARCH; DRUG TOLERABILITY; ESOPHAGUS CANCER; FAMILY HISTORY; GASTROESOPHAGEAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PERIOPERATIVE PERIOD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; SURVIVAL TIME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG RESISTANCE; EPSTEIN BARR VIRUS INFECTION; ESOPHAGEAL NEOPLASMS; GENETICS; GENOMICS; HELICOBACTER INFECTION; IMMUNOTHERAPY; PROCEDURES; PROGNOSIS; PROTO ONCOGENE; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPSTEIN-BARR VIRUS INFECTIONS; ESOPHAGEAL NEOPLASMS; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HELICOBACTER INFECTIONS; HUMANS; IMMUNOTHERAPY; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84959474547     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.15     Document Type: Review

References (162)

1. Ferlay J., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015
2. De Martel C., et al. Gastric cancer: epidemiology and risk factors. Gastroenterol. Clin. North Am. 42, 219-240 (2013
3. Colquhoun A., et al. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 64, 1881-1888 (2015
4. Kim J. Y., et al. Lymph node metastasis in early gastric cancer: evaluation of a novel method for measuring submucosal invasion and development of a nodal predicting index. Hum. Pathol. 44, 2829-2836 (2013
5. Gockel I., et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev. Gastroenterol. Hepatol. 5, 371-384 (2011
6. Wagner A. D., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 3, CD004064 (2010
7. Lordick F., et al. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 17, 213-225 (2014
8. Van Cutsem E., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24, 4991-4997 (2006
9. Van Cutsem E., et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann. Oncol. 26, 149-156 (2015
10. Bang Y. J., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010
11. Fuchs C. S., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31-39 (2014
12. Wilke H., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224-1235 (2014
13. Lordick F. Gastrointestinal cancer: over the RAINBOW - renaissance in antiangiogenesis. Nat. Rev. Clin. Oncol. 12, 7-8 (2015
14. Moehler M., et al. International comparison of the German evidence-based S3 guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 18, 550-563 (2015
15. National Comprehensive Cancer Network GuidelinesVersion 3.2015 Gastric Cancer. [online], http://www.nccn.org/professionals/physician-gls/PDF/gastric.pdf
16. Lauren P. The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965
17. Marrelli D., et al. Different patterns of recurrence in gastric cancer depending on Lauren's histologic type: longitudinal study. World J. Surg. 26, 1160-1165 (2002
18. Carneiro F., et al. Model of the early development of diffuse gastric cancer in E cadherin mutation carriers and it's implications for patient screening. J. Pathol. 203, 681-687 (2004
19. Yuo W. C., et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 53, 1317-1321 (1993
20. Correa P., et al. Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res. 50, 4731-4736 (1990
21. Anderson W. F., et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303, 1723-1728 (2010
22. Blot W. J., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265, 1287-1289 (1991
23. Crew K. D., & Neugut A. I. Epidemiology of gastric cancer. World J. Gastroenterol. 12, 354-362 (2006
24. Sakaguchi T., et al. Characteristics and clinical outcome of proximal-third gastric cancer. J. Am. Coll. Surg. 187, 352-357 (1998
25. Hofmann M., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52, 797-805 (2008
26. Tafe L. J., et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch. Pathol. Lab. Med. 135, 1460-1465 (2011
27. Steevens J., et al. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur. J. Gastroenterol. Hepatol. 22, 669-678 (2010
28. Marshall B. J., & Warren J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1314 (1984
29. Correa P. Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pathol. 19, S37-S43 (1995
30. Figueiredo C., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl Cancer Inst. 94, 1680-1687 (2002
31. Yang P., et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur. J. Cancer 45, 2867-2873 (2009
32. Tsugane S., & Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 10, 75-83 (2007
33. Mendez M. A., et al. Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study. Int. J. Cancer 121, 1618-1623 (2007
34. Lunet N., et al. Fruit and vegetables consumption and gastric cancer: a systematic review and meta-analysis of cohort studies. Nutr. Cancer 53, 1-10 (2005
35. Shibata D., et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am. J. Pathol. 139, 469-474 (1991
36. Kusano M., et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106, 1467-1479 (2006
37. Bass A. J., et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014
38. Cheng D. T., et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015
39. Memorial Sloan Kettering Cancer Center. cBioPortal for Cancer Genomics http://www.cbioportal.org/study.do?cancer-study-id=egc-tmucih-2015# summary
40. Gao J., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013
41. Riches J. C., et al. Genomic profiling of esophagogastric (EG) tumors in clinical practice [abstract]. J. Clin. Oncol. 33 (Suppl. 3), 57 (2015
42. Cristescu R., et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449-456 (2015
43. Janjigian Y. Y., et al. Patient-derived xenografts as models for the identification of predictive biomarkers in esophagogastric cancer [abstract]. J. Clin. Oncol. 32 (Suppl. 5), 4059 (2014
44. Fitzgerald R. C., et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J. Med. Genet. 47, 436-444 (2010
45. Guilford P., et al. E cadherin germline mutations in familial gastric cancer. Nature 392, 402-405 (1998
46. Huntsman D. G., et al. Early gastric cancer in young, asymptomatic carriers of germ-line E cadherin mutations. N. Engl. J. Med. 344, 1904-1909 (2001
47. Pharoah P. D., et al. Incidence of gastric cancer and breast cancer in CDH1 (E cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121, 1348-1353 (2001
48. Benusiglio P. R., et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J. Med. Genet. 50, 486-489 (2013
49. van Der Post R. S., et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 52, 361-374 (2015
50. Moran A., et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer 11, 235-242 (2012
51. Watanabe H., et al. Gastric lesions in familial adenomatosis coli: their incidence and histologic analysis. Hum. Pathol. 9, 269-283 (1978
52. Lynch H. T., et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104, 1535-1549 (1993
53. Jakubowska A., et al. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br. J. Cancer 87, 888-891 (2002
54. Oliveira C., et al. Genetic screening for hereditary diffuse gastric cancer. Expert Rev. Mol. Diagn. 3, 201-215 (2003
55. Worthley D. L., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61, 774-779 (2012
56. Oliveira C., et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 16, e60-e70 (2015
57. Hansford S., et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 1, 23-32 (2015
58. Hoskins L. C., et al. Distribution of ABO blood groups in patients with pernicious anemia, gastric carcinoma and gastric carcinoma associated with pernicious anemia. N. Engl. J. Med. 273, 633-637 (1965
59. Edgren G., et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am. J. Epidemiol. 172, 1280-1285 (2010
60. Won E., et al. HER2 directed therapy for gastric/esophageal cancers. Curr. Treat. Opt. Oncol. 15, 395-404 (2014
61. Zhang X. L., et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J. Surg. 33, 2112-2118 (2009
62. Begnami M. D., et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J. Clin. Oncol. 29, 3030-3036 (2011
63. Warneke V. S., et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann. Oncol. 24, 725-733 (2013
64. Katai H., et al. HER2 expression in carcinomas of the true cardia (Siewert type II esophagogastric junction carcinoma). World J. Surg. 38, 426-430 (2014
65. Nagatsuma A. K., et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 18, 227-238 (2015
66. Tanner M., et al. Amplification of HER 2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273-278 (2005
67. Janjigian Y. Y., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol. 23, 2656-2662 (2012
68. Terashima M., et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin. Cancer Res. 18, 5992-6000 (2012
69. Aizawa M., et al. Evaluation of HER2 based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer 17, 34-42 (2014
70. Okines A. F., et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann. Oncol. 24, 1253-1261 (2013
71. Wang T., et al. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum. Pathol. 45, 970-975 (2014
72. Gsmez-Mart'n C., et al. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin. Transl. Oncol. 13, 636-651 (2011
73. Lordick F. HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clin. Transl. Oncol. 13, 597-598 (2011
74. Gullo I., et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc. Int. Open 3, E165-E170 (2015
75. Tominaga N., et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer http://dx.doi.org/10.1007/s10120-015-0502-3 (2015
76. Kushima R., et al. Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program. Virchows Arch. 464, 539-545 (2014
77. Gomez-Martin C., et al. Level of HER2 gene amplification predicts response and overall survival in HER2 positive advanced gastric cancer treated with trastuzumab. J. Clin. Oncol. 31, 4445-4452 (2013
78. Rüschoff J., et al. HER2 testing in gastric cancer: a practical approach. Mod. Pathol. 25, 637-650 (2012
79. Wainberg Z. A., et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2 amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16, 1509-1519 (2010
80. Satoh T., et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer in Asian populations: TyTAN - a randomized, phase III study. J. Clin. Oncol. 32, 2039-2049 (2014
81. Hecht J. R., et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2 positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO 013/LOGiC - a randomized phase III Trial. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.62.6598 (2015
82. Lorenzen S., et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2 amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur. J. Cancer 51, 569-576 (2015
83. Blackwell K. L., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol. 30, 2585-2592 (2012
84. Yamashita-Kashima Y., et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2 positive human gastric cancer xenograft models. Clin. Cancer Res. 17, 5060-5070 (2011
85. Kang Y. K., et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2 positive advanced gastric cancer. Br. J. Cancer 111, 660-666 (2014
86. Tabernero J., et al. Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2 positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB) [abstract]. J. Clin. Oncol. 31 (Suppl.), TPS4150 (2013
87. Kang Y. K., et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2 positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC) [abstract]. J. Clin. Oncol. 34 (Suppl. 4s), 5 (2016
88. Rivera F., et al. NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma - R0 resection, pCR, and toxicity analysis [abstract]. J. Clin. Oncol. 31 (Suppl.), 4098, (2013
89. Hofheinz R. D., et al. HER-FLOT: trastuzumab in combination with FLOT as perioperative treatment for patients with HER2 positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the AIO Gastric Cancer Study Group [abstract]. J. Clin. Oncol. 32 (Suppl.), 4073 (2014
90. U.S. National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02205047 (2015
91. U.S. National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01196390 (2015
92. Japan Clinical Oncology Group. A randomized phase II study of sysemic chemotherapy with and without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis (Trastuzumab In Gastric or Esophagogastric junction Adenocarcinoma): trigger study. [online], http://www.jcog.jp/document/1301.pdf
93. GBG GERMAN BREAST GROUP, et al. Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression. Breast Care (Basel) 3, 364-365 (2008
94. Jackisch C., et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in Germany. Breast 23, 603-608 (2014
95. Arteaga C. L., & Engelman J. A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282-303 (2014
96. Janjigian Y. Y., et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2 overexpressing esophagogastric (EG) tumors treated with trastuzumab. J. Clin. Oncol. 33 (Suppl. 3), 63 (2015
97. Leyland-Jones B., et al. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J. Clin. Oncol. 28, 960-966 (2010
98. Oude Munnink T. H., et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2 positive tumor load. J. Clin. Oncol. 28, e355-e356; author reply e357 (2010
99. Dijkers E. C., et al. Biodistribution of 89Zr trastuzumab and PET imaging of HER2 positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586-592 (2010
100. Oude Munnink T. H., et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2 positive tumor load. J. Clin. Oncol. 28, e355-e356 (2010
101. Janjigian Y. Y., et al. Monitoring afatinib treatment in HER2 positive gastric cancer with 18F FDG and 89Zr trastuzumab PET. J. Nucl. Med. 54, 936-943 (2013
102. Lordick F., et al. Cetuximab plus oxaliplatin/leucovorin/5 fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Cancer 102, 500-505 (2010
103. Luber B., et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5 fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 11, 509 (2011
104. Lordick F., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 490-499 (2013
105. Waddell T., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 481-489 (2013
106. Dragovich T., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24, 4922-4927 (2006
107. Dutton S. J., et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 15, 894-904 (2014
108. Petty R. D., et al. Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG) [abstract]. J. Clin. Oncol. 32 (Suppl.), 4016 (2014
109. Deng N., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co occurrence among distinct therapeutic targets. Gut 61, 673-684 (2012
110. Lennerz J. K., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011
111. Iveson T., et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose De escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 15, 1007-1018 (2014
112. Lordick F. Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol. 15, 914-916 (2014
113. Cunningham D., et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET 1 study [abstract]. J. Clin. Oncol. 33 (Suppl.), 4000 (2015
114. Shah M., et al. METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2 negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC) [abstract]. J. Clin. Oncol. 33 (Suppl.), 4012 (2015
115. Kawakami H., et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 4, 9-17 (2013
116. Kwak E. L., et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer [abstract]. J. Clin. Oncol. 33 (Suppl. 3), 01 (2015
117. Xie L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19, 2572-2583 (2013
118. Bang J. Y., et al. A randomized, open-label phase II study of AZD4547 (AZD) versus paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study [abstract]. J. Clin. Oncol. 33 (Suppl.), 4014 (2015
119. Smyth E. C., et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours [abstract]. J. Clin. Oncol. 33 (Suppl.), 2508 (2015
120. Ohtsu A., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE 1 study. J. Clin. Oncol. 31, 3935-3943 (2013
121. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971
122. Hanahan D., & Weinberg R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
123. Clarke J. M., & Hurwitz H. I. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin. Biol. Ther. 13, 1187-1196 (2013
124. Thuss-Patience P. C., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306-2314 (2011
125. Kang J. H., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 30, 1513-1518 (2012
126. Ford H. E., et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR 02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 15, 78-86 (2014
127. Hironaka S., et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J. Clin. Oncol. 31, 4438-4444 (2013
128. Li J., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J. Clin. Oncol. 31, 3219-3225 (2013
129. Anastassiadis T., et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011
130. Wilhelm S., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844 (2006
131. Janjigian Y. Y., et al. Phase II trial of sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer. PLoS ONE 10, e0134731 (2015
132. Pavlakis N., et al. INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): a study by the Australasian Gastrointestinal Trials Group (AGITG) - final overall and subgroup results [abstract]. J. Clin. Oncol. 33 (Suppl.), 4003 (2015
133. Ohtsu A., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968-3976 (2011
134. Shen L., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 18, 168-176 (2015
135. Yoon H. H., et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE AC): randomized, double-blind, multicenter phase 2 trial [abstract]. J. Clin. Oncol. 32 (Suppl.), 4004 (2014
136. Erber R., et al. Combined inhibition of VEGF-and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18, 338-340 (2004
137. Fischer C., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007
138. Fuchs C. S., et al. A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117) [abstract]. J. Clin. Oncol. 33 (Suppl.), TPS4131 (2015
139. Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119-2127 (2012
140. Lapidot T., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 17, 645-648 (1994
141. Kaiser J. The cancer stem cell gamble. Science 347, 226-229 (2015
142. Patrawala L., et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65, 6207-6219 (2005
143. Patrawala L., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696-1708 (2006
144. Vermeulen L., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010
145. Vries R. G., et al. Stem cells and cancer of the stomach and intestine. Mol. Oncol. 4, 373-384 (2010
146. Marx J. Cancer's perpetual source? Science 317, 1029-1031 (2007
147. Scheitz C. J., et al. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J. 31, 4124-4139 (2012
148. Yu H., et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736-746 (2014
149. Susman S., et al. The Lauren classification highlights the role of epithelial-to mesenchymal transition in gastric carcinogenesis: an immunohistochemistry study of the STAT3 and adhesion molecules expression. J. Gastrointestin. Liver Dis. 24, 77-83 (2015
150. Li Y., et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc. Natl Acad. Sci. USA 112, 1839-1844 (2015
151. Shah M. A., et al. The BRIGHTER trial: a phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma [abstract]. J. Clin. Oncol. 33 (Suppl.), PS4139 (2015
152. Lawrence M. S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013
153. Lesokhin A. M., et al. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 7, 280sr1 (2015
154. Doi T., et al. Pembrolizumab (MK 3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE 028 [abstract]. J. Clin. Oncol. 33 (Suppl.), 4010 (2015
155. Muro K., et al. Relationship between PD L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti PD 1 monoclonal antibody pembrolizumab (Pembro; MK 3475) in KEYNOTE 012 [abstract]. J. Clin. Oncol. 33 (Suppl. 3), 03 (2015
156. Curran M. A., et al. PD 1 and CTLA 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275-4280 (2010
157. Duraiswamy J., et al. Dual blockade of PD 1 and CTLA 4 combined with tumor vaccine effectively restores T cell rejection function in tumors. Cancer Res. 369, 122-133 (2013
158. Callahan M., et al. Phase I/II, open-label study of nivolumab (anti PD 1; BMS 936558, ONO 4538) as monotherapy or combined with ipilimumab advanced or metastatic solid tumor [abstract]. J. Clin. Oncol. 32 (Suppl.), TPS3114 (2014
159. Tran E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014
160. Papa S., et al. Clinical evaluation of ErbB-targeted CAR T cells, following intracavity delivery in patients with ErbB-expressing solid tumors. Methods Mol. Biol. 1317, 365-382 (2015
161. Ahmed N., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2 positive sarcoma. J. Clin. Oncol. 33, 1688-1696 (2015
162. Lin S. J., et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 64, 1721-1731 (2015